DNA repair in cancer: emerging targets for personalized therapy
Rachel Abbotts, Nicola Thompson, Srinivasan Madhusudan University of Nottingham, Academic Unit of Oncology, Division of Oncology, School of Medicine, Nottingham University Hospitals, City Hospital Campus, Nottingham, UK Abstract: Genomic deoxyribonucleic acid (DNA) is under constant threat from en...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-02-01
|
Series: | Cancer Management and Research |
Online Access: | http://www.dovepress.com/dna-repair-in-cancer-emerging-targets-for-personalized-therapy-a15867 |
id |
doaj-dcc541db552e4b95b76d29d8f36e590c |
---|---|
record_format |
Article |
spelling |
doaj-dcc541db552e4b95b76d29d8f36e590c2020-11-24T22:47:55ZengDove Medical PressCancer Management and Research1179-13222014-02-012014default779215867DNA repair in cancer: emerging targets for personalized therapyAbbotts RThompson NMadhusudan S Rachel Abbotts, Nicola Thompson, Srinivasan Madhusudan University of Nottingham, Academic Unit of Oncology, Division of Oncology, School of Medicine, Nottingham University Hospitals, City Hospital Campus, Nottingham, UK Abstract: Genomic deoxyribonucleic acid (DNA) is under constant threat from endogenous and exogenous DNA damaging agents. Mammalian cells have evolved highly conserved DNA repair machinery to process DNA damage and maintain genomic integrity. Impaired DNA repair is a major driver for carcinogenesis and could promote aggressive cancer biology. Interestingly, in established tumors, DNA repair activity is required to counteract oxidative DNA damage that is prevalent in the tumor microenvironment. Emerging clinical data provide compelling evidence that overexpression of DNA repair factors may have prognostic and predictive significance in patients. More recently, DNA repair inhibition has emerged as a promising target for anticancer therapy. Synthetic lethality exploits intergene relationships where the loss of function of either of two related genes is nonlethal, but loss of both causes cell death. Exploiting this approach by targeting DNA repair has emerged as a promising strategy for personalized cancer therapy. In the current review, we focus on recent advances with a particular focus on synthetic lethality targeting in cancer. Keywords: biomarker, drug target, synthetic lethalityhttp://www.dovepress.com/dna-repair-in-cancer-emerging-targets-for-personalized-therapy-a15867 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Abbotts R Thompson N Madhusudan S |
spellingShingle |
Abbotts R Thompson N Madhusudan S DNA repair in cancer: emerging targets for personalized therapy Cancer Management and Research |
author_facet |
Abbotts R Thompson N Madhusudan S |
author_sort |
Abbotts R |
title |
DNA repair in cancer: emerging targets for personalized therapy |
title_short |
DNA repair in cancer: emerging targets for personalized therapy |
title_full |
DNA repair in cancer: emerging targets for personalized therapy |
title_fullStr |
DNA repair in cancer: emerging targets for personalized therapy |
title_full_unstemmed |
DNA repair in cancer: emerging targets for personalized therapy |
title_sort |
dna repair in cancer: emerging targets for personalized therapy |
publisher |
Dove Medical Press |
series |
Cancer Management and Research |
issn |
1179-1322 |
publishDate |
2014-02-01 |
description |
Rachel Abbotts, Nicola Thompson, Srinivasan Madhusudan University of Nottingham, Academic Unit of Oncology, Division of Oncology, School of Medicine, Nottingham University Hospitals, City Hospital Campus, Nottingham, UK Abstract: Genomic deoxyribonucleic acid (DNA) is under constant threat from endogenous and exogenous DNA damaging agents. Mammalian cells have evolved highly conserved DNA repair machinery to process DNA damage and maintain genomic integrity. Impaired DNA repair is a major driver for carcinogenesis and could promote aggressive cancer biology. Interestingly, in established tumors, DNA repair activity is required to counteract oxidative DNA damage that is prevalent in the tumor microenvironment. Emerging clinical data provide compelling evidence that overexpression of DNA repair factors may have prognostic and predictive significance in patients. More recently, DNA repair inhibition has emerged as a promising target for anticancer therapy. Synthetic lethality exploits intergene relationships where the loss of function of either of two related genes is nonlethal, but loss of both causes cell death. Exploiting this approach by targeting DNA repair has emerged as a promising strategy for personalized cancer therapy. In the current review, we focus on recent advances with a particular focus on synthetic lethality targeting in cancer. Keywords: biomarker, drug target, synthetic lethality |
url |
http://www.dovepress.com/dna-repair-in-cancer-emerging-targets-for-personalized-therapy-a15867 |
work_keys_str_mv |
AT abbottsr dnarepairincanceremergingtargetsforpersonalizedtherapy AT thompsonn dnarepairincanceremergingtargetsforpersonalizedtherapy AT madhusudans dnarepairincanceremergingtargetsforpersonalizedtherapy |
_version_ |
1725680515934060544 |